Closing the Gaps in NSCLC
Closing the Gaps in NSCLC
ReachMD
Understanding the Importance of RET Mutation as a Primary Oncogenic Driver
1 seconds Posted Apr 13, 2021 at 4:00 am.
0:00
0:01
Download MP3
Show notes
Guest: Edward S. Kim, MD

When looking at the non-small cell lung cancer landscape, we’re now seeing the emergence of several genetic markers that may have therapies linked to them, and one of those markers is the RET fusion that exists. Join Dr. Edward Kim as he gets us caught up on the investigational therapies targeting RET-mutated non-small cell lung cancer that just might end up in the clinic.